Antihyperlipidemic Drugs Market to Hit USD 20.1 Bn by 2031 | Transparency Market Research Wilmington, Delaware, United States, March 27, 2023 (GLOBE NEWSWIRE) -- According to the exhaustive antihyperlipidemic drugs market report by TMR, the global industry was valued USD 12.0 Bn in 2022...

PCSK9 Inhibitors Market Sales to expand at a 15.8% CAGR from 2023 to 2033, Repatha-based Inhibitors to be Most Widely Used: Future Market Insights, Inc. NEWARK, Del, Jan. 11, 2023 (GLOBE NEWSWIRE) -- A recently published study by FMI expects the global PCSK9 inhibitors market to augment at a 15.8% CAGR from 2022 to 2032. By the end of the said...

PCSK9 Barriers Survey Results Revealed at National Lipid Association Conference PHOENIX, AZ--(Marketwired - February 07, 2017) - As part of its Spring Clinical Lipid Update (CLU) in Phoenix, the National Lipid Association (NLA) will reveal the results of its "Challenges in...

Cholesterol-Lowering Injectables: More Harm Than Good, States Journal of American Physicians and Surgeons TUCSON, Ariz., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Newly approved cholesterol lowering agents, Repatha (evolocumab) and Praluent (alirocumab), are being heavily promoted as a new breakthrough in...